Sezary Syndrome (Stage IV)

Failed 1 Systemic Therapy
- LYMHL0142
  - Phase II MK-3475 (Pembrolizumab) & Interferon Gamma 1-b +/- Immunotherapy in Previously Treated MF/SS
  - PI: Kim
  - CITN
- LYMHL0136
  - Phase I Duvelisib in Combo w/ Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
  - PI: Kim
  - Memorial Sloan Kettering
- LYMHL0138
  - Phase I/2A Cerdulatinib (PRT062070) in Relapsed/Refractory CLL or SLL B Cell or T-Cell NHL
  - PI: Kim
  - Portola Pharmaceuticals

Failed 2 Systemic Therapies
- LYMHL0146
  - Phase 1a/1b TTI-621 Targeting CD47 in Relapsed/Refractory Hematologic Malignancies & Solid Tumors
  - PI: Kim
  - Pending

Failed 3 Systemic Therapies
- LYMHL0103
  - Phase III Safety and Efficacy of E7777 (Denileukin Diftux) in Persistent/Recurrent Cutaneous NHL
  - PI: Kim
  - Esai Oncology Franchise

- LYMHL0145
  - Phase III Topical Naloxone Hydrochloride Lotion 0.5% in MF or SS Forms of Cutaneous T-Cell Lymphoma
  - PI: Kim
  - Sponsor: Elfarac Inc.